La Fundaci\u00f3 \u201dla\u00a0Caixa\u201d impulsa 15 projectes de recerca biom\u00e8dica capdavantera d\u2019Espanya i Portugal en la convocat\u00f2ria CaixaResearch Validate 2022. Es tracta de projectes en estadi inicial als quals l\u2019entitat vol donar suport per accelerar la seva arribada al mercat i acostar-los, aix\u00ed, als pacients que els puguin necessitar.<\/p>\n
Un panel d\u2019experts europeus i professionals de l\u2019\u00e0mbit de les ci\u00e8ncies de la vida i de la salut ha seleccionat aquests 15 projectes d\u2019entre els 110 presentats a la convocat\u00f2ria. Els escollits han rebut fins a 100.000 euros per validar les seves tecnologies i dissenyar un full de ruta per fer-ne la valoraci\u00f3.<\/p>\n
El projecte d\u2019en Josep Maria Aran impulsat per aquestes pret\u00e9n desenvolupar un f\u00e0rmac per la malaltia inflamat\u00f2ria intestinal. Uns 3 milions de persones a Europa pateixen malaltia inflamat\u00f2ria intestinal (MII), d\u2019origen autoimmune, amb un impacte econ\u00f2mic en els sistemes de salut p\u00fablics d\u2019entre 4.600 i 5.600 milions d\u2019euros anuals. A Espanya, la incid\u00e8ncia d\u2019aquest grup de malalties, en les quals s\u2019inclouen la colitis ulcerosa i la malaltia de Crohn, \u00e9s de 14,7 casos per cada 100.000 habitants. Tenen un impacte negatiu considerable en la qualitat de vida dels pacients, el 10-15 % dels quals necessitaran en darrer terme sotmetre\u2019s a una intervenci\u00f3 quir\u00fargica per extirpar part del c\u00f2lon. Aquestes malalties, a m\u00e9s, comporten un risc associat de desenvolupar c\u00e0ncer colorectal.<\/p>\n
Hi ha alguns tractaments, per\u00f2 els pacients solen presentar un compliment baix a causa dels seus efectes secundaris. A m\u00e9s, poden causar immunosupressi\u00f3, cosa que pot derivar en problemes de salut importants. Es necessiten f\u00e0rmacs m\u00e9s segurs, amb menys efectes secundaris i amb m\u00e9s efic\u00e0cia.<\/p>\n
En aquest sentit, els investigadors d\u2019aquest projecte han descobert una prote\u00efna de la sang que t\u00e9 una capacitat antiinflamat\u00f2ria molt elevada: \u00e9s capa\u00e7 de fer que les c\u00e8l\u00b7lules del sistema immunitari passin d\u2019estar en un estat proinflamatori a un estat antiinflamatori, cosa que podria frenar la progressi\u00f3 d\u2019aquestes malalties. A partir d\u2019aquesta prote\u00efna reguladora del sistema immunitari innat, que \u00e9s la primera l\u00ednia defensiva del cos, han desenvolupat una prote\u00efna recombinant, PRP-HO7, que, administrada en les dosis apropiades i en el moment prec\u00eds, \u00e9s capa\u00e7 d\u2019aturar la inflamaci\u00f3, restaurar la toler\u00e0ncia immunit\u00e0ria i aconseguir la remissi\u00f3 a llarg termini de la MII sense causar immunosupressi\u00f3.<\/p>\n
En aquest projecte, els investigadors volen posar a punt aquest f\u00e0rmac biol\u00f2gic per poder fer un assaig cl\u00ednic en fase I per a la MII.<\/p>\n
<\/p>\n
<\/p>\n
L\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l’Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l’Institut Catal\u00e0 de la Salut, l’Institut Catal\u00e0 d’Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n L\u2019IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L’any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" El projecte del Dr. Aran pret\u00e9n desenvolupar un f\u00e0rmac per la malaltia inflamat\u00f2ria intestinal.<\/p>\n","protected":false},"author":8,"featured_media":21887,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[334,464,378],"tags":[],"class_list":["post-21886","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicina-translacional","category-p-de-gens-malaltia-i-terapia","category-processos-immune-inflamatoris-i-terapia-genica"],"publishpress_future_action":{"enabled":false,"date":"2024-09-14 18:57:12","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/21886"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=21886"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/21886\/revisions"}],"predecessor-version":[{"id":21888,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/21886\/revisions\/21888"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/21887"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=21886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=21886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=21886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}